切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2022, Vol. 15 ›› Issue (04) : 494 -497. doi: 10.3877/cma.j.issn.1674-6902.2022.04.009

论著

PROX1对早期非小细胞肺癌微创切除术后复发的预测意义
魏东1, 辛运超2, 刘博3, 容宇1, 李彦明1, 郝雁冰1,†()   
  1. 1. 075000　张家口，河北北方学院附属第一医院胸外科
    2. 075000　张家口，河北北方学院附属第一医院耳鼻咽喉头颈外科
    3. 075000　张家口，河北北方学院附属第一医院病理科
  • 收稿日期:2022-05-17 出版日期:2022-08-25
  • 通信作者: 郝雁冰
  • 基金资助:
    河北省卫建委重点科技研究计划(20200552)

Predictive value of PROX1 for recurrence after minimally invasive resection of early non-small cell lung cancer

Dong Wei1, Yunchao Xin2, Bo Liu3, Yu Rong1, Yanming Li1, Yanbing Hao1,†()   

  1. 1. Thoracic Surgery, First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China
    2. Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China
    3. Pathology Department of First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China
  • Received:2022-05-17 Published:2022-08-25
  • Corresponding author: Yanbing Hao
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

魏东, 辛运超, 刘博, 容宇, 李彦明, 郝雁冰. PROX1对早期非小细胞肺癌微创切除术后复发的预测意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 494-497.

Dong Wei, Yunchao Xin, Bo Liu, Yu Rong, Yanming Li, Yanbing Hao. Predictive value of PROX1 for recurrence after minimally invasive resection of early non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(04): 494-497.

目的

分析Prospero相关同源异形盒蛋白1(PROX1)对早期非小细胞肺癌(NSCLC)微创切除术后复发的预测意义。

方法

选择2019年12月至2021年12月我院收治的54例拟接受微创切除术的NSCLC患者，采用免疫组织化学染色法检测患者NSCLC癌组织和对应癌旁组织中PROX1表达情况。统计NSCLC复发情况，比较复发者与未复发者临床资料，采用Logistic多因素回归分析影响NSCLC患者术后复发的因素，采用受试者工作特征曲线(ROC)分析NSCLC癌组织中PROX1表达水平预测术后复发。

结果

癌组织中PROX1表达水平比癌旁组织高(P<0.05)，癌组织中PROX1高表达例数比癌旁组织高(P<0.05)；13例患者复发(24.07%)。复发患者淋巴结转移、PROX1高表达、TNM分期为Ⅱ期例数比未复发患者高(P<0.05)；Logistic多因素回归分析显示PROX1高表达、淋巴结转移、TNM分期为Ⅱ期是NSCLC术后复发危险因素(P<0.05)；ROC分析显示，癌组织中PROX1表达水平预测NSCLC术后复发的最佳截点为8.36，灵敏度为84.78%，特异度为89.13%。

结论

NSCLC癌组织PROX1高表达，PROX1蛋白表达是NSCLC术后复发的危险因素，为预测NSCLC术后复发的指标。

关键词: Prospero相关同源异形盒蛋白1, 非小细胞肺癌, 微创切除术
Objective

To investigate the predictive value of Prospero related homeobox protein 1 (PROX1) in the recurrence of early non-small cell lung cancer (NSCLC) after minimally invasive resection.

Methods

54 patients with NSCLC who were admitted to the hospital from June 2016 to December 2018 to undergo minimally invasive resection were selected as the research objects. The expression of PROX1 in NSCLC tissues and corresponding adjacent tissues was detected by immunohistochemical staining. The recurrence of NSCLC patients was counted, and the clinical characteristics of relapsed patients and non relapsed patients were compared. The factors affecting postoperative recurrence of NSCLC patients were analyzed by logistic regression analysis. The PROX1 expression level in NSCLC cancer tissue was analyzed by receiver operating characteristic curve (ROC) to predict the efficacy of postoperative recurrence.

Results

the expression level of PROX1 in cancer tissues was higher than that in adjacent tissues (P<0.05), and the number of cases with high expression of PROX1 in cancer tissues was higher than that in adjacent tissues (P<0.05), 24 patients relapsed, and the recurrence rate was 25.53% (24/54). The number of cases with lymph node metastasis, high expression of PROX1 and TNM stage Ⅱ in the recurrent group was higher than that in the non recurrent group (P<0.05), Logistic regression analysis showed that high expression of PROX1, lymph node metastasis and TNM stage Ⅱ were independent risk factors for postoperative recurrence of NSCLC (P<0.05), ROC analysis showed that the best cutoff point for predicting postoperative recurrence of NSCLC patients by PROX1 expression level in cancer tissues was 8.36, the sensitivity was 84.78%, the specificity was 89.13%, and the area under the curve (AUC) was 0.930 (P<0.05).

Conclusion

the expression of PROX1 in cancer tissues of NSCLC patients is high, and the expression level of PROX1 protein is an independent risk factor for postoperative recurrence of NSCLC patients, which can be used as a sensitive index to predict postoperative recurrence of NSCLC patients.

Key words: Prospero related homeobox protein 1, Non small cell lung cancer, Minimally invasive resection
表1 复发与未复发患者临床特征比较[n(%)]
临床资料 复发(n＝13) 未复发(n＝41) t/χ2值 P值
病理类型        
  腺癌 10(79.93) 25(60.98) 1.101 0.294
  鳞癌 3(23.08) 16(39.02)    
TNM分期        
  Ⅰ期 1(7.69) 15(36.59) 3.952 0.047
  Ⅱ期 12(92.31) 26(63.41)    
淋巴结转移        
  有 8(61.53) 12(29.27) 4.408 0.036
  无 5(38.46) 29(70.73)    
术后辅助治疗        
  有 9(69.23) 26(63.41) 0.146 0.702
  无 4(30.77) 15(36.59)    
PROX1表达情况        
  高表达 9(69.23) 12(29.27) 6.633 0.010
  低表达 4(30.77) 29(70.73)    
吸烟史        
  有 10(79.93) 25(60.98) 1.101 0.294
  无 3(23.08) 16(39.02)    
分化程度        
  低分化 7(53.85) 29(70.73) 1.266 0.260
  中/高分化 6(46.15) 12(29.27)    
肿瘤直径(cm) 5.28±1.31 5.32±1.34 0.127 0.899
手术方式        
  全肺切除 3(23.08) 12(29.27) 0.189 0.664
  肺叶切除 10(79.93) 29(70.73)    
病灶部位        
  左肺 6(46.15) 18(43.90) 0.020 0.887
  右肺 7(53.85) 23(56.10)    
表2 Logistic多因素分析
因　素 β S.E. Wald P值 OR 95%CI
PROX1高表达 1.214 0.345 12.382 0.000 1.214 1.385~8.183
淋巴结转移 1.132 0.411 7.586 0.006 1.132 1.276~7.539
TNM分期为Ⅱ期 0.984 0.387 6.465 0.008 0.984 1.101~6.501
1
李树斌，于　鸿，张耿月. 厄洛替尼耐药的非小细胞肺癌细胞的差异表达mRNAs和lncRNAs分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(3): 365-371.
2
陈　燏，王玉秀，闵凌峰. NIX蛋白表达与非小细胞肺癌临床病理特征及预后[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 412-416.
3
乔天运，熊延路，冯杨波，等. 非小细胞肺癌中肿瘤微环境细胞的表达特点及其与临床生存概率的相关性[J]. 现代肿瘤医学，2021, 29(5): 777-781.
4
张文静，徐　瑜，白　莉. 晚期非小细胞肺癌分子靶向治疗现状与研究进展[J]. 国际呼吸杂志，2021, 41(5): 332-338.
5
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
6
Sankar K, Gadgeel SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer[J]. Expert Rev Anticancer Ther, 2020, 20(8): 647-661.
7
Sun X, Huang T, Zhang C, et al. Long non-coding RNA LINC00968 reduces cell proliferation and migration and angiogenesis in breast cancer through up-regulation of PROX1 by reducing hsa-miR-423-5p[J]. Cell Cycle, 2019, 18(16): 1908-1924.
8
Rudzinska M, Mikula M, Arczewska KD, et al. Transcription factor prospero homeobox 1 (PROX1) as a potential angiogenic regulator of follicular thyroid cancer dissemination[J]. Int J Mol Sci, 2019, 20(22): 5619.
9
周清华，王　瑾，许　峰. 2005年美国国家综合癌症网(NCCN)非小细胞肺癌临床指南[J]. 中国肺癌杂志，2005, 8(4): 332-346.
10
Vanderlaan PA. Non-small cell lung cancer predictive biomarker testing via immunocytochemistry: Ways of future past？[J]. Cancer Cytopathol, 2019, 127(5): 278-280.
11
祝国芸，向朝雪，林　骏，等. 长链非编码RNA GIHCG对非小细胞肺癌恶性表型的影响[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(6): 727-732.
12
Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: Immunotherapy[J]. Clin Chest Med, 2020, 41(2): 237-247.
13
Hua Q, Jin M, Mi B, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis[J]. J Hematol Oncol, 2019, 12(1): 91.
14
Hafez AM, Harb OA, Alattar AZ, et al. Clinico-pathological and prognostic implications of Srx, Nrf2, and PROX1 expression in gastric cancer and adjacent non-neoplastic mucosa-an immunohistochemical study[J]. Contemp Oncol (Pozn), 2020, 24(4): 229-240.
15
郭雁翔，郭　欢，张斌明. 乳腺癌组织中PROX1的表达和临床病理参数之间的相关性及其共表达基因分析[J]. 中国妇幼保健，2019, 34(8): 1879-1884.
16
Lo RG, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade[J]. Clin Cancer Res, 2019, 25(3): 989-999.
17
Meng FW, Jing XN, Song GH, et al. Prox1 induces new lymphatic vessel formation and promotes nerve reconstruction in a mouse model of sciatic nerve crush injury[J]. J Anat, 2020, 237(5): 933-940.
18
景子涵，车德海，于　雁. ⅢA(N2)期非小细胞肺癌术后不良预后影响因素及术后辅助治疗的研究进展[J]. 癌症进展，2019, 17(7): 760-764.
19
田翠孟，李宝兰. ⅢA-N2期非小细胞肺癌根治术后放疗疗效影响因素的研究进展[J]. 中华放射肿瘤学杂志，2020, 29(10): 909-912.
20
鲍　慧，年　亮，秦妮娜. 不同基因分型复发或转移晚期非小细胞肺癌患者的临床特征及预后影响因素分析[J]. 癌症进展，2019, 17(18): 2162-2166.
21
付　强，孙克林. Ⅰa期非小细胞肺腺癌亚肺叶切除术后复发的影响因素研究进展[J]. 癌症进展，2019, 17(5): 510-513, 581.
22
顾安康，陈凤鸣，王　雷. D2-40和Prox1在弥漫性躯体性血管角化瘤及行性血管瘤中的表达差异[J]. 中华皮肤科杂志，2019, 52(11): 817-820.
23
Zhu X, Chen Y, Zhu W, et al. Oroxylin A inhibits Kaposi′s sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARgamma/Prox1 axis[J]. J Med Virol, 2019, 91(3): 463-472.
24
李　冰，马起鹏，林　林. Prospero相关同源异形盒蛋白1在宫颈癌组织中的表达及其临床意义[J]. 东南大学学报(医学版), 2021, 40(3): 376-380.
25
杨　光，张　昆，王　俊. Prospero相关同源异形盒蛋白1在非小细胞肺癌中的表达及意义[J]. 中国癌症杂志，2020, 30(10): 791-797+811.
26
袁　超，高洪波，周　磊. 鸡Prox1基因重组真核表达载体的构建及其表达特征分析[J]. 农业生物技术学报，2020, 28(8): 1450-1457.
27
李　聪，李　翠，杨美娇. 乳腺癌患者组织中PROX1的表达水平及与预后的相关性分析[J]. 中国医药科学，2020, 10(14): 199-202.
28
Gramolelli S, Elbasani E, Tuohinto K, et al. Oncogenic herpesvirus engages endothelial transcription factors SOX18 and PROX1 to increase viral genome copies and virus production[J]. Cancer Res, 2020, 80(15): 3116-3129.
29
Choi D, Park E, Kim KE, et al. The lymphatic cell environment promotes kaposi sarcoma development by prox1-enhanced productive lytic replication of kaposi sarcoma herpes virus[J]. Cancer Res, 2020, 80(15): 3130-3144.
30
Aguilar B, Choi I, Choi D, et al. Lymphatic reprogramming by Kaposi sarcoma herpes virus promotes the oncogenic activity of the virus-encoded G-protein-coupled receptor[J]. Cancer Res, 2012, 72(22): 5833-5842.
31
Elbasani E, Gramolelli S, Günther T, et al. Kaposi′s sarcoma-associated herpesvirus lytic replication is independent of anaphase-promoting complex activity[J]. J Virol, 2020, 94(13): e02079-e02019.
32
Pantry SN, Medveczky PG. Epigenetic regulation of Kaposi′s sarcoma-associated herpesvirus replication[J]. Semin Cancer Biol, 2009, 19(3): 153-157.
[1] 徐天亮, 程干思, 吴亚平, 龚荣, 胡洁, 段群娣, 李承慧. 奥希替尼联合安罗替尼二线治疗转移性NSCLC的疗效分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 520-522.
[2] 魏婷婷, 胡小红, 龚自强, 熊鹿. 老年非小细胞肺癌组织ARPC2表达及与预后关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 584-586.
[3] 杜静怡, 徐兴祥. 循环肿瘤细胞在非小细胞肺癌中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 596-600.
[4] 黄承路, 廖飞, 刘显平, 王志强. 血清外泌体Has_circ_0060937过度表达与NSCLC转移和不良预后的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 490-494.
[5] 陈坤, 何傅梅, 方婷, 陈文瑞. 血清sCD73与EGFR/ALK野生型非小细胞肺癌免疫治疗效果的相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 504-507.
[6] 朱超男, 王帅, 王文博, 郑贸根, 程远, 陈志全. 非小细胞肺癌患者组织miR-31-5p表达与临床病理特征及预后的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 508-510.
[7] 杨豪, 王云川, 陈有英. 硬膜外阻滞复合羟考酮镇痛在非小细胞肺癌患者中的应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 370-372.
[8] 李咏生, 孙建国, 李梦侠, 重庆肺癌精准治疗协作组(CPLOG). 第三代EGFR-TKI耐药后诊疗策略专家共识[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 145-155.
[9] 仇丽敏, 胡航, 孙云浩, 孙健, 陈婷婷. NSCLC患者根治性切除术后复发风险分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 242-244.
[10] 邹琴, 龙玲, 叶容, 张小洪. PD-1抑制剂免疫治疗NSCLC所致反应性毛细血管增生症的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 278-280.
[11] 李多, 郝昭昭, 陈延伟, 南岩东. Wnt/β-Catenin通路促进非小细胞肺癌转移机制研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 281-284.
[12] 钱小卫, 丁海兵, 游继军, 王熠, 卞小霞. 微小miR水平联合检测在非小细胞肺癌转移中的意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 47-50.
[13] 李一然, 王玉秀, 朱研, 王梦, 刘颖, 闫文锦, 徐兴祥, 闵凌峰. 基于GEO数据库分析影响纳武单抗及派姆单抗治疗非小细胞肺癌疗效的差异基因[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 20-25.
[14] 汪涛, 朱浩雨, 卜青松, 胡磊, 王文娟, 方阮, 刘啸峰. 非小细胞肺癌EGFR突变状态与CT特征的相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 51-54.
[15] 曹玲莉, 涂平华, 吴展陵, 李新军. NK细胞、Treg细胞、T淋巴亚群在NSCLC外周血中表达及临床意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 55-57.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号